2017 ACVIM Forum Research Abstract Program

Current supplementation protocols for CBL in dogs call for parenteral (PE) supplementation. In humans, several studies have reported equal efficacy of PE and oral (PO) supplementation of CBL. Recently, this group has reported successful PO CBL supplementation in dogs with CE and hypocobalaminemia in a retrospective observational study and in a prospective study comparing oral and parenteral CBL supplementation. The purpose of this retrospective study was to evaluate the effect on PO CBL supplementation in dogs with EPI and subnormal or low-normal serum CBL concentrations. A computerized database search for dogs treated at Evidensia Specialist Animal Hospital, Helsingborg, Sweden during 2010-2016 was performed. Inclusion criteria were dogs diagnosed with EPI based on subnormal serum canine trypsin-like immunoreactivity concentration (cTLI; reference range 5-35 lg/ L), an initial serum cobalamin concentration ≤ 350 ng/L (reference interval: 234-811 ng/L), and daily treatment with CBL tablets (cyanocobalamin 1 mg/tablet; dogs < 20 kg ¼ tablet/10 kg, dogs ≥ 20 kg 1 tablet). Exclusion criteria were PE CBL supplementation in parallel with PO or failure to comply with the treatment protocol.